Axsome Therapeutics, Inc.
Clinical trials sponsored by Axsome Therapeutics, Inc., explained in plain language.
A biopharmaceutical company developing central nervous system therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to keep night shift workers awake and safe Results expected Dec 2026 (estimated)
- New drug could curb binge eating episodes Results expected Dec 2026 (estimated)
-
Can a Once-Daily pill offer safe, Long-Term ADHD control for kids?
Disease control By invitation onlyThis Phase 3 trial is evaluating how safe solriamfetol is when taken daily over a long period by children and adolescents with ADHD. Participants who completed earlier studies will receive the medication and be monitored for side effects. The goal is to see if this treatment rema…
Phase 3 • Sponsor: Axsome Therapeutics, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New pill shows promise for Long-Term control of binge eating
Disease control By invitation onlyThis Phase 3 study tests the long-term safety and effectiveness of the drug solriamfetol in 300 adults with binge eating disorder. Participants take a daily pill (75, 150, or 300 mg) and are monitored for side effects and changes in binge eating. The study is open-label, meaning …
Phase 3 • Sponsor: Axsome Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New fibromyalgia drug shows promise in Long-Term safety trial
Symptom relief By invitation onlyThis study tests the long-term safety and effectiveness of an experimental drug called AXS-14 for people with fibromyalgia, a condition causing widespread pain and fatigue. About 300 adults who previously took part in a related study will receive AXS-14 for 52 weeks. Researchers …
Phase 3 • Sponsor: Axsome Therapeutics, Inc. • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC